Business
Devonian Health Group Announces Publication of Landmark Study Highlighting Thykamine™ as a Promising New Anti-Inflammatory Agent
Devonian Health Group Inc. ("Devonian" or the "Corporation") (TSXV: GSD) (OTCQB: DVHGF), a biopharmaceutical corporation specializing in the development of prescription drugs targeting fibroinflammatory diseases, is pleased to announce the publication of a peer-reviewed article in Biomedicines titled "Thykamine™: A New Player in the Field of Anti-Inflammatory Drugs." The study presents notable evidence supporting the potent multi-target anti-inflammatory properties of Thykamine™, the Corporation
About this update from Devonian Health Group, Inc.
[{"type":"text","content":"QUÉBEC, Dec. 4, 2025 /CNW/ - Devonian Health Group Inc. ("Devonian" or the "Corporation") (TSXV: GSD) (OTCQB: DVHGF), a biopharmaceutical corporation specializing in the development of prescription drugs targeting fibroinflammatory diseases, is pleased to announce the publication of a peer-reviewed article in Biomedicines titled "Thykamine™: A New Player in the Field of Anti-Inflammatory Drugs." The study presents notable evidence supporting the potent multi-target anti-inflammatory properties of Thykamine™, the Corporation's lead pharmaceutical candidate.","length":601,"tagName":"p"},{"type":"image","alt":"Devonian Health Group Inc. Logo (CNW Group/Devonian Health Group Inc.)","displaySize":"","headline":null,"caption":"Devonian Health Group Inc. Logo (CNW Group/Devonian Health Group Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":356,"height":195,"url":"https://media.zenfs.com/en/prnewswire.com/3cc007b0cdf11ba9cfc6a2fb6424dccd"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Qn.h5Aj.D_iuEMyJep9O8Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM4NjtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/3cc007b0cdf11ba9cfc6a2fb6424dccd","width":356,"height":195}},"href":"https://mma.prnewswire.com/media/2837896/Devonian_Health_Group_Inc__Devonian_Health_Group_Announces_Publi.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The article, published in peer-reviewed BioMedicines Journal and titled, ''Thykamine™: A New Player in the Field of Anti-Inflammatory Drugs'', is now available online at: https://www.mdpi.com/2227-9059/13/12/2938. It was co-authored by Dr. Charles Lynde, Associate Professor in the Department of Medicine at the University of Toronto; Professor (Pr) Louis Flamand, Department of Microbiology, Infectious Disease and Immunology, Faculty of Medicine, Université Laval; Vincent McCarty and Dr. John Sampalis, Department of Surgery, McGill University, Montreal, Canada.","length":581,"tagName":"p"},{"type":"text","content":"In this study, researchers compared the effect of Thykamine™ with six widely prescribed anti-inflammatory drugs (including corticosteroids such as betamethasone, clobetasol, hydrocortisone, prednisone; and non-steroidal therapies such as crisaborole and pimecrolimus). Using an in vitro model of immune-act...